The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.. Dupilumab (Dupixent), a human monoclonal antibody that inhibits ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...